Ligand Pharmaceuticals (NASDAQ:LGND) Stock: Insider John Kozarich Sells 500 Shares

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director John Kozarich sold 500 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $325.00, for a total transaction of $162,500.00. Following the completion of the sale, the director owned 42,122 shares of the company’s stock, valued at approximately $13,689,650. The trade was a 1.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ LGND traded down $7.08 during midday trading on Monday, reaching $301.71. The company’s stock had a trading volume of 186,903 shares, compared to its average volume of 263,991. The stock has a market capitalization of $6.04 billion, a P/E ratio of 134.69, a PEG ratio of 5.39 and a beta of 1.16. The firm has a 50 day moving average price of $301.71 and a 200-day moving average price of $258.02. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19. Ligand Pharmaceuticals Incorporated has a 12-month low of $175.89 and a 12-month high of $326.63.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.34. The business had revenue of $78.75 million during the quarter, compared to the consensus estimate of $77.00 million. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The firm’s quarterly revenue was down 31.8% compared to the same quarter last year. During the same quarter last year, the company posted $3.09 earnings per share. As a group, equities analysts predict that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.

Hedge Funds Weigh In On Ligand Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC increased its position in shares of Ligand Pharmaceuticals by 2.5% during the third quarter. Global Retirement Partners LLC now owns 1,403 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 34 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Ligand Pharmaceuticals by 5.7% in the second quarter. GAMMA Investing LLC now owns 681 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 37 shares during the last quarter. Choreo LLC raised its stake in shares of Ligand Pharmaceuticals by 3.0% in the third quarter. Choreo LLC now owns 1,634 shares of the biotechnology company’s stock worth $510,000 after purchasing an additional 47 shares during the last quarter. Cim Investment Management Inc. lifted its holdings in shares of Ligand Pharmaceuticals by 3.4% during the first quarter. Cim Investment Management Inc. now owns 1,484 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 49 shares in the last quarter. Finally, Ethic Inc. lifted its holdings in shares of Ligand Pharmaceuticals by 7.4% during the third quarter. Ethic Inc. now owns 1,002 shares of the biotechnology company’s stock valued at $313,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 91.28% of the company’s stock.

Wall Street Analyst Weigh In

LGND has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price target on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a report on Friday, October 30th. Citigroup lifted their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $358.00 target price on shares of Ligand Pharmaceuticals in a report on Thursday, September 24th. Oppenheimer restated an “outperform” rating and issued a $326.00 price objective (up from $285.00) on shares of Ligand Pharmaceuticals in a report on Monday, August 3rd. Finally, Weiss Ratings cut shares of Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a report on Monday, November 2nd. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Ligand Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $355.38.

Check Out Our Latest Analysis on LGND

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Read More

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.